Last reviewed · How we verify

NCT06122519

Characteristics of Eye Diseases in Children and Adolescents With Autism Spectrum Disorders and the Effect of Corresponding Treatment on the Quality of Life of Children and Adolescents With Autism and Their Caregivers

Status unknown Last updated 8 November 2023
What this trial tests

trial in Autism Spectrum Disorder in 1,000 participants. Status unknown.

Timeline
1 April 2023
Primary endpoint
1 April 2024
1 April 2024

Quick facts

Lead sponsorTianjin Eye Hospital
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment1,000
Start date1 April 2023
Primary completion1 April 2024
Estimated completion1 April 2024
Sites1 location across China

Conditions studied

Sponsor

Tianjin Eye Hospital

Who can join

Adults 2 to 18, any sex, with Autism Spectrum Disorder or Visual Function. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study mainly investigated the incidence of eye diseases in children with autism spectrum disorder(ASD) in Tianjin area, and analyzed related risk factors, so as to raise attention to eye diseases in children with ASD. To evaluate the impact of ophthalmic treatment on the quality of life of children with autism and their primary caregivers.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Refractive Errors and Ocular Biometric Parameters in Children with Autism Spectrum Disorder in Handan: A Cross-Sectional Study.
    Cheng Y, Wang J, Liu M, Guo D, et al · · 2026 · PMID 41924538 · DOI 10.2147/ijgm.s572336

Verify or expand the search:

Other recruiting trials for Autism Spectrum Disorder

Currently open trials in the same condition.

Other Tianjin Eye Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06122519.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing